Loading organizations...
Halitus develops advanced breath analytics technology for disease detection and treatment. The company utilizes multimodal sensing and AI-powered analysis to identify exhaled biomarkers and their concentrations. This approach aims to provide biometric health summaries and enable real-time diagnostic insights through a non-invasive method, focusing on the potential of breath to reveal health status.
The company was founded to address the critical need for accessible, mobile, and immediate diagnostic tools in healthcare. Its inception was driven by the insight that human breath contains valuable diagnostic clues, offering a pathway to early disease detection and continuous patient monitoring. This foundation underscores a commitment to translating complex biological signals into actionable healthcare data.
Halitus’s services primarily target healthcare providers, with a specific focus on remote monitoring for oncology patients undergoing chemotherapy. The long-term vision is to integrate breath analytics into routine care, transforming disease detection and enabling more personalized and precise medical interventions. Halitus envisions a future where breath analysis is a ubiquitous, integral component of patient management.
Halitus has raised $1.0M across 1 funding round.
Halitus has raised $1.0M in total across 1 funding round.
Halitus has raised $1.0M in total across 1 funding round.
Halitus's investors include Better Ventures, Bjorn Kolbmuller, Dr. Cedric Duvinage, Julius Göllner, Mirko Caspar.
Halitus GmbH is a Berlin-based technology company developing non-invasive diagnostic tools that analyze exhaled breath to detect diseases through biomarkers.[1][2][3] It transforms complex medical sensor data, including the smallest molecules in breath, into actionable insights for healthcare applications like disease detection and precision medicine, serving patients and medical professionals.[1][5][6][7] The company operates at the intersection of health diagnostics, machine learning, and medical devices, with pre-seed funding of 1 million euros signaling early growth momentum in a nascent market.[3][5]
Halitus emerged from Berlin, Germany, as a startup focused on breath analysis technology, though specific founders and exact founding year are not detailed in available records.[3] The idea stems from advancing non-invasive diagnostics by detecting exhaled chemical biomarkers in real-time, building on sensor data processing and AI to interpret breath for bodily insights.[1][2][7] Early traction includes securing 1 million euros in pre-seed funding, highlighting pivotal validation from investors in health tech and machine learning sectors.[3][5]
Halitus rides the wave of AI-driven precision medicine and non-invasive diagnostics, capitalizing on trends in breathomics where exhaled molecules reveal metabolic and disease states.[2][6] Timing aligns with rising demand for quick, scalable health screening post-pandemic, fueled by advances in sensor tech and machine learning.[1][3] Market forces like aging populations and chronic disease prevalence favor breath-based tools for cost-effective early detection, positioning Halitus to influence healthcare by enabling point-of-care testing and reducing diagnostic burdens.[4][5][7]
Halitus is poised to scale its breath analytics platform through pilot evaluations and partnerships, potentially expanding to clinical trials and broader disease applications beyond initial biomarkers.[7] Trends like AI personalization in medtech and wearable integration will shape its path, amplifying non-invasive screening adoption.[6] Its influence may grow by setting standards in breathprinting, evolving from pre-seed innovator to key player in global health diagnostics—transforming breath into a vital health signal.[2][3]
Halitus has raised $1.0M across 1 funding round. Most recently, it raised $1.0M Seed in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 1, 2023 | $1M Seed | — | Better Ventures, Bjorn Kolbmuller, DR. Cedric Duvinage, Julius Göllner, Mirko Caspar | Announced |
